ASO Author Reflections: Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Surgical Conversion in Borderline Resectable Cholangiocarcinoma.
Saved in:
| Title: | ASO Author Reflections: Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Surgical Conversion in Borderline Resectable Cholangiocarcinoma. |
|---|---|
| Authors: | Dong Y; Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA.; Department of Surgery, HPB Center, Vienna Health Network, Clinic Favoriten and Sigmund Freud Private University, Vienna, Austria., Starlinger P; Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA. Starlinger.Patrick@mayo.edu. |
| Source: | Annals of surgical oncology [Ann Surg Oncol] 2025 Oct; Vol. 32 (10), pp. 7262-7263. Date of Electronic Publication: 2025 Aug 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
| ISSN: | 1534-4681 |
|---|---|
| DOI: | 10.1245/s10434-025-18076-0 |
